1. Home
  2. FBIZ vs PRTA Comparison

FBIZ vs PRTA Comparison

Compare FBIZ & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Business Financial Services Inc.

FBIZ

First Business Financial Services Inc.

HOLD

Current Price

$55.74

Market Cap

488.9M

Sector

Finance

ML Signal

HOLD

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

HOLD

Current Price

$10.65

Market Cap

539.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FBIZ
PRTA
Founded
1909
2012
Country
United States
Ireland
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
488.9M
539.9M
IPO Year
2012
2013

Fundamental Metrics

Financial Performance
Metric
FBIZ
PRTA
Price
$55.74
$10.65
Analyst Decision
Strong Buy
Buy
Analyst Count
4
9
Target Price
$65.00
$19.00
AVG Volume (30 Days)
40.3K
419.1K
Earning Date
04-23-2026
05-07-2026
Dividend Yield
2.37%
N/A
EPS Growth
14.23
N/A
EPS
5.94
N/A
Revenue
N/A
$814,000.00
Revenue This Year
$15.69
$1,111.38
Revenue Next Year
$8.47
N/A
P/E Ratio
$9.67
N/A
Revenue Growth
N/A
N/A
52 Week Low
$45.90
$4.32
52 Week High
$60.54
$11.69

Technical Indicators

Market Signals
Indicator
FBIZ
PRTA
Relative Strength Index (RSI) 46.02 60.60
Support Level $53.56 $9.69
Resistance Level $59.76 $10.90
Average True Range (ATR) 1.36 0.35
MACD -0.20 -0.00
Stochastic Oscillator 20.26 70.47

Price Performance

Historical Comparison
FBIZ
PRTA

About FBIZ First Business Financial Services Inc.

First Business Financial Services Inc operates as a bank holding company. The Bank operates as a business bank, delivering a full line of commercial banking products, including commercial loans and commercial real estate loans, to meet the specific needs of small and medium-sized businesses, business owners, executives, professionals, and high-net-worth individuals. The company's products and services include commercial lending, SBA lending and servicing, asset-based lending, equipment financing, factoring, trust, and investment services, treasury management services, and a broad range of deposit products. Geographically, all the business activity functioned through the region of the United States.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Share on Social Networks: